The effect of a selective cyclooxygenase-2 inhibitor (celecoxib) on chronic periodontitis

Journal of Periodontology

Volumn 79, Issue 1, 2008, Pages 104-113

  Alec Yen, C ^a   Damoulis, Petros D ^a   Stark, Paul C ^b   Hibberd, Patricia L ^c   Singh, Medha ^a   Papas, Athena S ^a  

^a TUFTS UNIVERSITY SCHOOL OF DENTAL MEDICINE   (United States)

^b TUFTS MEDICAL CENTER   (United States)

^c TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Anti inflammatory agents, non steroidal; Cyclooxygenase 2; Cyclooxygenase inhibitors; Periodontitis

Indexed keywords

CELECOXIB; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; PROSTAGLANDIN SYNTHASE INHIBITOR; PYRAZOLE DERIVATIVE; SULFONAMIDE;

ADOLESCENT; ADULT; AGED; ARTICLE; CHRONIC DISEASE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; FOLLOW UP; GINGIVA BLEEDING; HUMAN; MALE; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PERIODONTAL DISEASE; PERIODONTITIS; PHASE 4 CLINICAL TRIAL; PREVENTIVE DENTISTRY; RANDOMIZED CONTROLLED TRIAL; TOOTH PLAQUE; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CHRONIC DISEASE; COMBINED MODALITY THERAPY; CYCLOOXYGENASE INHIBITORS; DENTAL PLAQUE INDEX; DENTAL SCALING; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; GINGIVAL HEMORRHAGE; HUMANS; MALE; MIDDLE AGED; PERIODONTAL ATTACHMENT LOSS; PERIODONTAL POCKET; PERIODONTITIS; PLACEBOS; PYRAZOLES; ROOT PLANING; SULFONAMIDES; TOOTH MOBILITY; TREATMENT OUTCOME;

EID: 38549085888     PISSN: 00223492     EISSN: None     Source Type: Journal    
DOI: 10.1902/jop.2008.070271     Document Type: Article

References (54)

1. Oliver RC, Brown LJ, Löe H. Periodontal diseases in the United States population. J Periodontol 1998;69: 269-278.
2. Brown LJ, Brunelle JA, Kingman A. Periodontal status in the United States, 1988-91: Prevalence, extent, and demographic variation. J Dent Res 1996;75:672-683.
3. U.S. Department of Health and Human Services. Healthy People 2010, 2nd ed. With Understanding and Improving Health and Objectives for Improving Health, 2 vols. Washington, DC: U.S. Government Printing Office; 2000:21-20.
4. Haffajee AD, Socransky SS. Microbial etiological agents of destructive periodontal disease. Periodontol 2000 1994;5:78-111.
5. Page RC, Schroeder HE. Pathogenesis of inflammatory periodontal disease. A summary of current work. Lab Investig 1976;34:235-249.
6. Kornman KS, Page RC, Tonetti MS. The host response to the microbial challenge in periodontitis: Assembling the players. Periodontol 2000 1997;14:33-53.
7. Schwartz Z. Mechanisms of alveolar bone destruction in periodontitis. Periodontol 2000 1997;14:158-172.
8. Hausmann E. Periodontal breakdown: A result of inadequate repair? J Periodontol 1992;63:58-60.
9. Alexander MB, Damoulis PD. The role of cytokines in the pathogenesis of periodontal disease. Curr Opin Periodontol 1994;2:39-53.
10. Gemmell E, Marshall RI, Seymour GJ. Cytokines and prostaglandins in immune homeostasis and tissue destruction in periodontal disease. Periodontol 2000 1997; 14:112-143.
11. 2 secretion as a determinant of periodontal disease expression. J Periodontol 1993;64:432-444.
12. Noguchi K, Shitashige M, Yanai M, et al. Prostaglandin production via induction of cyclooxygenase-2 by human gingival fibroblasts stimulated with lipopolysaccharides. Inflammation 1996;20:555-568.
13. Matejka M, Partyka L, Ulm C, Solar P, Sinzinger H. Nitric oxide synthesis is increased in periodontal disease. J Periodontal Res 1998;33:517-518.
14. Shoji M, Tanabe N, Mitsui N, et al. Lipopolysaccharide stimulates the production of prostaglandin E2 and the receptor Ep4 in osteoblasts. Life Sci 2006;78:2012-2018.
15. American Academy of Periodontology. Parameter on chronic periodontitis with advanced loss of periodontal support. J Periodontol 2000;71(5 Suppl.):856-858.
16. Howell TH. Blocking periodontal disease progression with anti-inflammatory agents. J Periodontol 1993; 64(8 Suppl.):828-833.
17. Reddy M, Geurs N, Gunsolley J. Periodontal host modulation with antiproteinase, anti-inflammatory, and bone-sparing agents. A systematic review. Ann Periodontol 2003;8:12-37.
18. Jeffcoat MK, Reddy MS, Haigh S, et al. A comparison of topical ketorolac, systemic flurbiprofen, and placebo for the inhibition of bone loss in adult periodontitis. J Periodontol 1995;66:329-338.
19. Paquette DW, Lawrence HP, McCombs GB, et al. Pharmacodynamic effects of ketoprofen on crevicular fluid prostanoids in adult periodontitis. J Clin Periodontol 2000;27:558-566.
20. Offenbacher S, Williams RC, Jeffcoat MK, et al. Effects of NSAIDs on beagle crevicular cyclooxygenase metabolites and periodontal bone loss. J Periodontal Res 1992;27:207-213.
21. Williams RC, Jeffcoat MK, Howell TH, et al. Altering the progression of human alveolar bone loss with the non-steroidal anti-inflammatory drug flurbiprofen. J Periodontol 1989;60:485-490.
22. Williams RC, Jeffcoat MK, Howell TH, et al. Indomethacin or flurbiprofen treatment of periodontitis in beagles: Comparison of effect on bone loss. J Periodontal Res 1987;22:403-407.
23. Vardar S, Buduneli E, Baylas H, et al. Individual and combined effects of selective cyclooxygenase-2 inhibitor and omega-3 fatty acid on endotoxin-induced periodontitis in rats. J Periodontol 2005;76:99-106.
24. 2 and IL-6 production by human gingival fibroblasts. J Periodontol 2003;74:1754-1763.
25. O'Leary T, Drake R, Naylor J. The plaque control record. J Periodontol 1972;43:38.
26. Schluger S. Periodontal Disease: Basic Phenomena, Clinical Management, and Occlusal and Restorative Interrelationships, 2nd ed. Philadelphia: Lea & Febiger; 1990:322.
27. Knowles JW, Burgett FG, Nissle RR, Shick RA, Morrison EC, Ramfjord SP. Results of periodontal treatment related to pocket depth and attachment level. Eight years. J Periodontol 1979;50:225-233.
28. Caton J, Ciancio S, Blieden T, et al. Treatment with subantimicrobial dose doxycycline improves the efficacy of scaling and root planing in patients with adult periodontitis. J Periodontol 2000;71:521-532.
29. Robinson WS. Ecological correlations and the behavior of individuals. Sociol Rev 1950;15:351-357.
30. Laird N, Ware H. Random-effects models for longitudinal data. Biometrics 1982;38:963-974.
31. Rosenberg D. The future of medicine: Your health in the 21st century. Newsweek. June 10, 2005:70.
32. Haffajee AD, Socransky SS, Lindhe J, Kent RL, Okamoto H, Yoneyama T. Clinical risk indicators for periodontal attachment loss. J Clin Periodontol 1991; 18:117-125.
33. Grbic JT, Lamster IB. Risk indicators for future clinical attachment loss in adult periodontitis. Tooth and site variables. J Periodontol 1992;63:262-269.
34. Haffajee AD, Socransky SS, Goodson JM. Clinical parameters as predictors of destructive periodontal disease activity. J Clin Periodontol 1983;10:257-265.
35. Halazonetis TD, Haffajee AD, Socransky SS. Relationship of clinical parameters to attachment loss in subsets of subjects with destructive periodontal diseases. J Clin Periodontol 1989;16:563-568.
36. Badersten A, Nilveus R, Egelberg J. Reproducibility of probing attachment level measurements. J Clin Periodontol 1984;11:475-485.
37. Isidor F, Karring T, Attstrom R. Reproducibility of pocket depth and attachment level measurements when using a flexible splint. J Clin Periodontol 1984; 11:662-668.
38. Pihlstrom BL, Ortiz-Campos C, McHugh RB. A randomized four-year study of periodontal therapy. J Periodontol 1981;52:227-242.
39. Hammerle CHF, Joss A, Lang NP. Short-term effects of initial periodontal therapy (hygienic phase). J Clin Periodontol 1991;18:233-239.
40. Hill RW, Ramfjord SP, Morrison EC, et al. Four types of periodontal treatment compared over two years. J Periodontol 1981;52:655-662.
41. Nordland P, Garrett S, Kiger R, Vanooteghem R, Hutchens LH, Egelberg J. The effect of plaque control and root debridement in molar teeth. J Clin Periodontol 1987;14:231-236.
42. Ng VW-K, Bissada NF. Clinical evaluation of systemic doxycycline and ibuprofen administration as an adjunctive treatment for adult periodontitis. J Periodontol 1998;69:772-776.
43. Brägger U, Mühle T, Fourmousis I, Lang NP, Mombelli A. Effect of the NSAID flurbiprofen on remodeling after periodontal surgery. J Periodontal Res 1997;32:575-582.
44. Reddy MS, Palcanis KG, Barnett ML, et al. Efficacy of meclofenamate sodium (Meclomen) in the treatment of rapidly progressive periodontitis. J Clin Periodontol 1993;20:635-640.
45. Haffajee AD, Dibart S, Kent RI, et al. Clinical and microbiological changes associated with the use of 4 adjunctive systemically administered agents in the treatment of periodontal infections. J Clin Periodontol 1995; 22:618-627.
46. Flemmig TF, Rumetsch M, Klaiber B. Efficacy of systemically administered acetylsalicylic acid plus scaling on periodontal health and elastase-α 1-preteinase inhibitor in gingival crevicular fluid. J Clin Periodontol 1996;23:153-159.
47. Jeffcoat MK, Williams RC, Reddy MS, et al. Flurbiprofen treatment of human periodontitis: Effect on alveolar bone height and metabolism. J Periodontal Res 1988;23:381-385.
48. Kaldahl WB, Kalkwarf KL, Patil KD, Dyer JK, Bates RE Jr. Evaluation of four modalities of periodontal therapy. Mean probing depth, probing attachment level and recession changes. J Periodontol 1988;59:783-793.
49. Loos B, Claffey N, Egelberg J. Clinical and microbiological effects of root debridement in periodontal furcation pockets. J Clin Periodontol 1988;15:453-463.
50. Williams RC, Jeffcoat MK, Howell TH, et al. Three-year trial of flurbiprofen treatment in humans: Post-treatment period. J Dent Res 1991;70:1617.
51. Jeffcoat MK, Page R, Reddy M, et al. use of digital radiography to demonstrate the potential of naproxen as an adjunct in the treatment of rapidly progressive periodontitis. J Periodontal Res 1991;26:415-421.
52. Heasman PA, Offenbacher S, Collins JG, et al. Flurbiprofen in the prevention and treatment of experimental gingivitis. J Clin Periodontol 1993;20: 732-738.
53. McGettigan P, Henry D. Cardiovascular risk and inhibition of cyclooxygenase. A systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase-2. JAMA 2006;296:1633-1644.
54. Solomon S, Pfeffer M, McMurray J, et al. Effect of celecoxib on cardiovascular events and blood pressure in the two trials for the prevention of colorectal adenomas. Circulation 2006;114:1028-1035.